Eli Lilly, Boehringer Ingelheim tout pivotal heart failure win for Jardiance, potentially setting up a Novartis showdown

The major market for chronic heart failure — until recently an indication without a single approved therapy — has evolved into a horse race in recent months with some big-name drugmakers in the lead. A few steps behind Novartis, Eli Lilly and Boehringer Ingelheim are touting new data for SGLT2 inhibitor Jardiance they think will get the drug across the finish line.